A 24-week Open-Label, Phase 3b Trial With a 28-week Extension to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin Compared to Insulin Glargine in Subjects withType 2 Diabetes Who Have Glycemic Control on Metformin

ClinicalTrials.gov ID: NCT02551874

Public ClinicalTrials.gov record NCT02551874. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced May 13, 2026, 10:25 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A 24-week International, Multicenter, Randomized, Open-Label, Active-Controlled, Parallel Group, Phase 3b Trial With a 28-week Extension to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin Compared to Insulin Glargine in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin With or Without Sulfonylurea Therapy

Study identification

NCT ID: NCT02551874
Recruitment status: Completed
Study type: Interventional
Phase: Phase 3
Lead sponsor: AstraZeneca; Industry
Enrollment: 650 participants

Conditions and interventions

Conditions

Type 2 Diabetes Mellitus

Interventions

Dapagliflozin, Farxiga Drug
Glargine insulin Drug
Metformin Drug
Saxagliptin, Onglyza Drug

Drug

Eligibility (public fields only)

Age range: 18 Years to 120 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Oct 19, 2015
Primary completion: May 7, 2017
Completion: Nov 9, 2017
Last update posted: Dec 10, 2018

2015 – 2017

United States locations

U.S. sites: 20
U.S. states: 13
U.S. cities: 18

Facility	City	State	ZIP	Site status
Research Site	Anaheim	California	92801	—
Research Site	Los Angeles	California	90057	—
Research Site	Miami	Florida	33144	—
Research Site	Miami	Florida	33155	—
Research Site	St. Petersburg	Florida	33709	—
Research Site	Norcross	Georgia	30071	—
Research Site	Chicago	Illinois	60612	—
Research Site	Lexington	Kentucky	40502	—
Research Site	Quincy	Massachusetts	02169	—
Research Site	Beavercreek	Ohio	45432	—
Research Site	Norman	Oklahoma	73069	—
Research Site	Barto	Pennsylvania	19504	—
Research Site	Columbia	South Carolina	29204	—
Research Site	Bristol	Tennessee	37620	—
Research Site	Kingsport	Tennessee	37660	—
Research Site	Houston	Texas	77004	—
Research Site	Mesquite	Texas	74194	—
Research Site	San Antonio	Texas	78230	—
Research Site	San Antonio	Texas	78258	—
Research Site	Bountiful	Utah	84010	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 20 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT02551874, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Dec 10, 2018 · Synced May 13, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02551874 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →